Subscribe to Our Blog
Receive updates from our team as we share application notes, customer spotlights, educational tools, spectroscopy how-to’s, and more.
We have joined a consortium of more than 20 organizations dedicated to assessing and implementing process analytical technologies to accelerate cell and gene therapy development and manufacturing.
Orlando, Florida, USA (June 2021) – Ocean Insight, the applied spectral knowledge company, has joined a consortium of more than 20 organizations dedicated to assessing and implementing process analytical technologies to accelerate cell and gene therapy development and manufacturing. Formed by the Cell and Gene Therapy Catapult, an independent center of excellence in the United Kingdom, the first-of-its-kind consortium comprises pharmaceutical companies, technology providers, therapy developers and charities.
As a technology provider, Ocean Insight will provide a combination of optical sensing products and applications know-how in support of process analytical technologies (PAT). PAT is a critical element of monitoring and controlling the production of cell and gene therapy biomaterials.
Cell therapy is the introduction of new cells into a patient to treat a disease. Gene therapy involves the use of modified DNA or RNA to prevent or treat diseases including Alzheimer’s and cancer. These technologies are on the leading edge of biomedical research, with hundreds of clinical trials in progress worldwide.
“Ocean Insight welcomes the opportunity to collaborate in the effort to advance cell and gene therapies, which are changing the way we treat disease,” said Jim Jenson, General Manager for Ocean Insight Core Technologies. “This initiative dovetails with our mission to create optical solutions that enable researchers and manufacturers to solve important issues in health, safety and the environment.”
For three decades, Ocean Insight spectrometers and sensing technologies have been part of biomedical and life sciences research and development for life-saving technologies. Our products are enabling applications including point-of-care blood gas analysis, bacteria and virus detection including COVID-19, quality control of catheters, burn and wound analysis, and early detection of pancreatic cancer.
Organizations that are part of the consortium are ABER Instruments; Anthony Nolan Cell & Gene Therapy Services; BD (Becton, Dickinson); Bio-Techne; Cambridge Consultants; Cell and Gene Therapy Catapult; ChemoMetec; C-CIT Sensors, Cytiva; Eppendorf; GlaxoSmithKline (GSK); HORIBA; IMSPEX Diagnostics Ltd.; Kaiser Optical Systems, an Endress+Hauser company; Lonza; Ocean Insight; Ori Biotech; Oxford Nanoimaging; Quantex; See-Through; TeloNostiX; Terumo Blood and Cell Technologies; and Univercells Technologies.